TuHURA Biosciences (HURA) vs Inovio Pharmaceuticals (INO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Inovio Pharmaceuticals (INO) over the past year, losing 24.0% versus a loss of 56.6%. Over five years, INO leads with a -98.6% price change compared with -99.9% for HURA. TuHURA Biosciences is the larger company by market cap ($124.9 million vs $118.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | INO |
|---|---|---|
| Share price | $1.96 | $1.15 |
| Market cap | $124.90M | $118.91M |
| 1-day change | +1.55% | +5.50% |
| YTD return | +158.92% | -33.91% |
| 1-year return | -24.03% | -56.60% |
| 5-year return | -99.87% | -98.63% |
| EPS (TTM) | $-0.54 | $-0.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.43 | $2.72 |
| 52-week low | $0.41 | $0.56 |
| Distance from 52-week high | -42.86% | -57.72% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +310.20% | +175.65% |
| Average volume | 244.46K | 3.88M |
| Shares outstanding | 63.73M | 103.40M |
| Employees | 22 | 112 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed INO by 32.6 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
HURA vs INO FAQ
Which is bigger, TuHURA Biosciences or Inovio Pharmaceuticals?
TuHURA Biosciences (HURA) is larger, with a market capitalization of $124.90M compared with $118.91M for Inovio Pharmaceuticals (INO).
Which stock has performed better over the past year, HURA or INO?
HURA returned -24.03% over the past 12 months, compared with -56.60% for INO (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and Inovio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.